Tafamidis

ATC N07XX08 · 10 markets · 29 records

Tafamidis 10 markets · 29 records Forms

AU 6 records · 3 strengths

61 mgcapsuleCIPLA TAFAMIDIS tafamidis 61 mg soft capsule blister pack+3TAFAMICIP tafamidis 61 mg soft capsule blister pack、Vyndamax、VYNDAMAX tafamidis 61 mg soft gelatin capsule blister pack also in US·GB·CA +4 unknown
20 mgcapsuleVYNDAQEL tafamidis meglumine 20 mg soft gelatin capsule blister pack also in US·GB·CA unknown

Records without a stated strength · 1 Vyndamax

US 2 records · 2 strengths

61 mgcapsuleVyndamax also in AU·GB·CA +4
20 mgcapsuleVyndaqel also in AU·GB·CA

GB 2 records · 2 strengths

61 mgcapsuleVyndaqel also in AU·US·CA +4
20 mgcapsuleVyndaqel also in AU·US·CA

CA 2 records · 2 strengths

61 mgcapsuleVyndamax also in AU·US·GB +4
20 mgcapsuleVyndaqel also in AU·US·GB

ES 2 records · 2 strengths

61 mgcapsuleVyndaqel also in AU·US·GB +4
12.2 mgcapsuleVyndaqel

HK 2 records · 1 strengths

Records without a stated strength · 1 Vyndamax、Vyndaqel

EU 2 records · 1 strengths

EU centralised authorisation (EMA) — Authorised at EU level — not a record of sale in any single country. The EU register carries no strength, dosage form or pack size.

Records without a stated strength · 1 TAFAMIDIS ACCORD、Vyndaqel

SG 1 records · 1 strengths

61 mgcapsuleVYNDAMAX SOFT GELATIN CAPSULE 61MG also in AU·US·GB +4

CN 1 records · 1 strengths

61 mgcapsule维万心氯苯唑酸 also in AU·US·GB +4

TW 1 records · 1 strengths

61 mgcapsuleVyndamax soft Capsules 61 mg+1維萬心軟膠囊61毫克 also in AU·US·GB +4

Side-by-side table

Strength / form / release	US	GB	CA	AU	SG	CN	ES	TW	HK	EU
61 mg capsule	Vyndamax	Vyndaqel	Vyndamax	CIPLA TAFAMIDIS tafamidis 61 mg soft capsule blister pack TAFAMICIP tafamidis 61 mg soft capsule blister pack Vyndamax +1 VYNDAMAX tafamidis 61 mg soft gelatin capsule blister pack	VYNDAMAX SOFT GELATIN CAPSULE 61MG	维万心氯苯唑酸	Vyndaqel	Vyndamax soft Capsules 61 mg 維萬心軟膠囊61毫克	not recorded	not recorded
20 mg capsule	Vyndaqel	Vyndaqel	Vyndaqel	VYNDAQEL tafamidis meglumine 20 mg soft gelatin capsule blister pack	not recorded	not recorded	not recorded	not recorded	not recorded	not recorded
12.2 mg capsule	not recorded	not recorded	not recorded	not recorded	not recorded	not recorded	Vyndaqel	not recorded	not recorded	not recorded
not disclosed unknown	not recorded	not recorded	not recorded	Vyndamax	not recorded	not recorded	not recorded	not recorded	Vyndamax Vyndaqel	TAFAMIDIS ACCORD Vyndaqel

Scroll horizontally for more markets →

Each country column shows the locally registered trade names — not translations.

1 more strength/form rows are recorded only in ES and are not shown in this table. Hay 1 filas de concentración/forma registradas solo en ES que no se muestran en esta tabla. 另有 1 个规格/剂型仅在 ES 有记录（未在本表显示）。另有 1 個規格/劑型僅在 ES 有記錄（未在本表顯示）。

“not disclosed” means the source does not publish the strength — it does not mean the product has none.

Hong Kong records are name/ingredient-level only: no strength, dosage form or registration status; on the register does not prove current supply.

Australia ARTG data has no registration-status column, so status is shown as unknown; being on the register does not mean currently marketed.

EU centralised authorisation (EMA) — Authorised at EU level — not a record of sale in any single country. The EU register carries no strength, dosage form or pack size.

Back to the list

The same ingredient can carry completely different brand names in different countries, and the same name can point to a different ingredient. Listed by country — not interchangeable.

Discontinued, withdrawn or unverified-status products are hidden by default; Hong Kong and Australia records are shown as exceptions.